119 related articles for article (PubMed ID: 9639806)
1. Lipids, lipoproteins and apolipoproteins abnormalities in patients undergoing dialysis.
Yang X; Wang H; Zhu Z; Deng A
J Tongji Med Univ; 1997; 17(2):126-8. PubMed ID: 9639806
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.
Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P
Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020
[TBL] [Abstract][Full Text] [Related]
3. Lipids, lipoproteins and apolipoproteins A-I and B and apolipoprotein losses in continuous ambulatory peritoneal dialysis.
Steele J; Billington T; Janus E; Moran J
Atherosclerosis; 1989 Sep; 79(1):47-50. PubMed ID: 2803346
[TBL] [Abstract][Full Text] [Related]
4. The uremic dyslipidemia: a cross-sectional and longitudinal study.
Avram MM; Goldwasser P; Burrell DE; Antignani A; Fein PA; Mittman N
Am J Kidney Dis; 1992 Oct; 20(4):324-35. PubMed ID: 1415199
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal survey of apolipoproteins and atherogenic risk in hemodialysis and continuous ambulatory peritoneal dialysis patients.
Burrell D; Antignani A; Fein PA; Goldwasser P; Mittman N; Avram MM
ASAIO Trans; 1990; 36(3):M331-5. PubMed ID: 2123635
[TBL] [Abstract][Full Text] [Related]
6. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
[TBL] [Abstract][Full Text] [Related]
7. Increased lipoprotein (a) and its relationships with other parameters of lipoprotein metabolism in chronic renal failure treated by hemodialysis.
Yiğitoğlu MR; Polat MF; Akçay F; Ari Z; Uyanik BS; Ozilgili HM
Jpn Heart J; 1997 Jan; 38(1):83-9. PubMed ID: 9186284
[TBL] [Abstract][Full Text] [Related]
8. Residual renal function affects lipid profile in patients undergoing continuous ambulatory peritoneal dialysis.
Kagan A; Elimalech E; Lemer Z; Fink A; Bar-Khayim Y
Perit Dial Int; 1997; 17(3):243-9. PubMed ID: 9237284
[TBL] [Abstract][Full Text] [Related]
9. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis.
Siamopoulos KC; Elisaf MS; Bairaktari HT; Pappas MB; Sferopoulos GD; Nikolakakis NG
Perit Dial Int; 1995; 15(8):342-7. PubMed ID: 8785232
[TBL] [Abstract][Full Text] [Related]
10. Apo A1/Apo B ratio and acute coronary syndrome among peritoneal dialysis patients.
Chen T; Yang M
Ren Fail; 2021 Dec; 43(1):737-742. PubMed ID: 33913384
[TBL] [Abstract][Full Text] [Related]
11. Hyperapobetalipoproteinemia: the major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis.
Sniderman A; Cianflone K; Kwiterovich PO; Hutchinson T; Barre P; Prichard S
Atherosclerosis; 1987 Jun; 65(3):257-64. PubMed ID: 3619989
[TBL] [Abstract][Full Text] [Related]
12. Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis.
Dieplinger H; Schoenfeld PY; Fielding CJ
J Clin Invest; 1986 Apr; 77(4):1071-83. PubMed ID: 3082933
[TBL] [Abstract][Full Text] [Related]
13. Increased activity of plasma cholesteryl ester transfer protein in children with end-stage renal disease receiving continuous ambulatory peritoneal dialysis.
Asayama K; Hayashibe H; Mishiku Y; Honda M; Ito H; Nakazawa S
Nephron; 1996; 72(2):231-6. PubMed ID: 8684532
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels.
Kagan A; Bar-Khayim Y; Schafer Z; Fainaru M
Kidney Int; 1990 Mar; 37(3):980-90. PubMed ID: 2313985
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients.
Fytili CI; Progia EG; Panagoutsos SA; Thodis ED; Passadakis PS; Sombolos KI; Vargemezis VA
Ren Fail; 2002 Sep; 24(5):623-30. PubMed ID: 12380908
[TBL] [Abstract][Full Text] [Related]
16. Ischemic heart disease, serum cholesterol, and apolipoproteins in CAPD.
Gault MH; Longerich L; Prabhakaran V; Purchase L
ASAIO Trans; 1991; 37(3):M513-4. PubMed ID: 1751258
[TBL] [Abstract][Full Text] [Related]
17. Variability of peritoneal clearances for apolipoprotein and its relationship to susceptibility for atherosclerotic changes in CAPD.
Fein PA; Fletcher D; Antignani A; Goldwasser P; Jorden A; Lustig A; Avram MM
Adv Perit Dial; 1989; 5():185-90. PubMed ID: 2577408
[TBL] [Abstract][Full Text] [Related]
18. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.
Nishizawa Y; Shoji T; Emoto M; Kawasaki K; Konishi T; Tabata T; Inoue T; Morii H
Clin Nephrol; 1995 Apr; 43(4):268-77. PubMed ID: 7606882
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein and lipid abnormalities in uremic children on hemodialysis.
Ohta T; Matsuda I
Clin Chim Acta; 1985 Apr; 147(2):145-54. PubMed ID: 3921292
[TBL] [Abstract][Full Text] [Related]
20. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
Milionis HJ; Elisaf MS; Karabina SA; Bairaktari E; Tselepis AD; Siamopoulos KC
Kidney Int; 1999 Dec; 56(6):2276-85. PubMed ID: 10594806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
